192 related articles for article (PubMed ID: 35994227)
1. Cost-Utility Analysis of CYP2C19 Genotype Detection for Selection of Acid-Suppressive Therapy with Lansoprazole or Vonoprazan for Patients with Reflux Esophagitis in China.
Zhang Z; Bao Y; Cai L; Gu Y; Yang T; Li X
Clin Drug Investig; 2022 Oct; 42(10):839-851. PubMed ID: 35994227
[TBL] [Abstract][Full Text] [Related]
2. Maintenance for healed erosive esophagitis: Phase III comparison of vonoprazan with lansoprazole.
Ashida K; Iwakiri K; Hiramatsu N; Sakurai Y; Hori T; Kudou K; Nishimura A; Umegaki E
World J Gastroenterol; 2018 Apr; 24(14):1550-1561. PubMed ID: 29662293
[TBL] [Abstract][Full Text] [Related]
3. Vonoprazan versus Lansoprazole for the Initial Treatment of Reflux Esophagitis: A Cost-effectiveness Analysis in Japan.
Habu Y
Intern Med; 2019 Sep; 58(17):2427-2433. PubMed ID: 31178490
[TBL] [Abstract][Full Text] [Related]
4. Vonoprazan Versus Lansoprazole for Healing and Maintenance of Healing of Erosive Esophagitis: A Randomized Trial.
Laine L; DeVault K; Katz P; Mitev S; Lowe J; Hunt B; Spechler S
Gastroenterology; 2023 Jan; 164(1):61-71. PubMed ID: 36228734
[TBL] [Abstract][Full Text] [Related]
5. Randomised clinical trial: vonoprazan, a novel potassium-competitive acid blocker, vs. lansoprazole for the healing of erosive oesophagitis.
Ashida K; Sakurai Y; Hori T; Kudou K; Nishimura A; Hiramatsu N; Umegaki E; Iwakiri K
Aliment Pharmacol Ther; 2016 Jan; 43(2):240-51. PubMed ID: 26559637
[TBL] [Abstract][Full Text] [Related]
6. Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial.
Xiao Y; Qian J; Zhang S; Dai N; Chun HJ; Chiu C; Chong CF; Funao N; Sakurai Y; Eisner JD; Xie L; Chen M
Chin Med J (Engl); 2024 Apr; 137(8):962-971. PubMed ID: 38654422
[TBL] [Abstract][Full Text] [Related]
7. Rapid metabolizer genotype of CYP2C19 is a risk factor of being refractory to proton pump inhibitor therapy for reflux esophagitis.
Ichikawa H; Sugimoto M; Sugimoto K; Andoh A; Furuta T
J Gastroenterol Hepatol; 2016 Apr; 31(4):716-26. PubMed ID: 26580676
[TBL] [Abstract][Full Text] [Related]
8. The Effects of Switching to Vonoprazan, a Novel Potassium-Competitive Acid Blocker, on Gastric Acidity and Reflux Patterns in Patients with Erosive Esophagitis Refractory to Proton Pump Inhibitors.
Yamashita H; Kanamori A; Kano C; Hashimura H; Matsumoto K; Tsujimae M; Yoshizaki T; Momose K; Obata D; Eguchi T; Fujita M; Okada A
Digestion; 2017; 96(1):52-59. PubMed ID: 28662503
[TBL] [Abstract][Full Text] [Related]
9. Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis.
Xiao Y; Zhang S; Dai N; Fei G; Goh KL; Chun HJ; Sheu BS; Chong CF; Funao N; Zhou W; Chen M
Gut; 2020 Feb; 69(2):224-230. PubMed ID: 31409606
[TBL] [Abstract][Full Text] [Related]
10. Vonoprazan versus proton-pump inhibitors for healing gastroesophageal reflux disease: A systematic review.
Miyazaki H; Igarashi A; Takeuchi T; Teng L; Uda A; Deguchi H; Higuchi K; Tango T
J Gastroenterol Hepatol; 2019 Aug; 34(8):1316-1328. PubMed ID: 30883868
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.
Tanabe T; Hoshino S; Kawami N; Hoshikawa Y; Hanada Y; Takenouchi N; Goto O; Kaise M; Iwakiri K
Esophagus; 2019 Oct; 16(4):377-381. PubMed ID: 31119492
[TBL] [Abstract][Full Text] [Related]
12. Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis.
Oshima T; Arai E; Taki M; Kondo T; Tomita T; Fukui H; Watari J; Miwa H
Aliment Pharmacol Ther; 2019 Jan; 49(2):140-146. PubMed ID: 30589965
[TBL] [Abstract][Full Text] [Related]
13. The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations.
Echizen H
Clin Pharmacokinet; 2016 Apr; 55(4):409-18. PubMed ID: 26369775
[TBL] [Abstract][Full Text] [Related]
14. Relationships of Proton Pump Inhibitor-Induced Renal Injury with CYP2C19 Polymorphism: A Retrospective Cohort Study.
Fukui R; Noda S; Ikeda Y; Sawayama Y; Terada T; Nakagawa Y; Morita SY
Clin Pharmacol Ther; 2024 May; 115(5):1141-1151. PubMed ID: 38258325
[TBL] [Abstract][Full Text] [Related]
15. Role of cytochrome P450 2C19 genetic polymorphisms in the therapeutic efficacy of omeprazole in Iranian patients with erosive reflux esophagitis.
Zendehdel N; Biramijamal F; Hossein-Nezhad A; Zendehdel N; Sarie H; Doughaiemoghaddam M; Pourshams A
Arch Iran Med; 2010 Sep; 13(5):406-12. PubMed ID: 20804307
[TBL] [Abstract][Full Text] [Related]
16. The effects of lansoprazole on erosive reflux oesophagitis are influenced by CYP2C19 polymorphism.
Kawamura M; Ohara S; Koike T; Iijima K; Suzuki J; Kayaba S; Noguchi K; Hamada S; Noguchi M; Shimosegawa T;
Aliment Pharmacol Ther; 2003 Apr; 17(7):965-73. PubMed ID: 12656699
[TBL] [Abstract][Full Text] [Related]
17. Comparative Efficacy of P-CAB vs Proton Pump Inhibitors for Grade C/D Esophagitis: A Systematic Review and Network Meta-analysis.
Zhuang Q; Chen S; Zhou X; Jia X; Zhang M; Tan N; Chen F; Zhang Z; Hu J; Xiao Y
Am J Gastroenterol; 2024 May; 119(5):803-813. PubMed ID: 38345252
[TBL] [Abstract][Full Text] [Related]
18. Genetic polymorphisms of CYP2C19 and IL1B have no influence on esomeprazole treatment for mild erosive esophagitis.
Hsu WH; Kuo FC; Hu HM; Hsu PI; Wu DC; Kuo CH
Kaohsiung J Med Sci; 2015 May; 31(5):255-9. PubMed ID: 25910560
[TBL] [Abstract][Full Text] [Related]
19. Cost-utility analysis of a 'vonoprazan-first' strategy versus 'esomeprazole- or rabeprazole-first' strategy in GERD.
Yokoya Y; Igarashi A; Uda A; Deguchi H; Takeuchi T; Higuchi K
J Gastroenterol; 2019 Dec; 54(12):1083-1095. PubMed ID: 31396703
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Vonoprazan Compared With Proton Pump Inhibitors in Patients Taking Low-Dose Aspirin for Secondary Prevention of Cardiovascular Events in Japan.
Ishii M; Kawai T; Tsujita K; Igarashi A; Suzuki M; Deguchi H; Fernandez J
Circ J; 2023 Jan; 87(2):348-359. PubMed ID: 36002313
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
